SCHEMBL15425987

SCHEMBL15425987

c1ccc(CN2CCSC23CCNCC3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
HIF1A Q16665 1/20 0.51
SIGMAR1 Q99720 3/20 0.47
CYP2D6 P10635 3/20 0.47
CYP3A4 P08684 2/20 0.41
HSD17B10 Q99714 1/20 0.41
HTR3A P46098 1/20 0.38
USP2 O75604 1/20 0.37
SOS1 Q07889 1/20 0.37
HPGD P15428 1/20 0.36
TACR1 P25103 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25055588 0.91 MEN1 (0.46) TSHRMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL25055582 0.84 SIGMAR1 (0.42) TSHRMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL25055722 0.83 CYP2D6 (0.50) TSHRMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL25055546 0.76 CYP2D6 (0.58) TSHRMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL12625908 0.75 CHRM2 (0.59) TSHRMEN1ALDH1A1CYP2C19KMT2A
SCHEMBL12625907 0.75 CYP2D6 (0.57) TSHRMEN1ALDH1A1CYP2C9CYP2C19
SCHEMBL25055762 0.73 OPRD1 (0.49) TSHRMEN1ALDH1A1CYP2C9KMT2A
SCHEMBL25055627 0.73 OPRD1 (0.49) MEN1ALDH1A1KMT2ACYP2D6CYP3A4
SCHEMBL25055564 0.73 CYP2D6 (0.44) TSHRMEN1KMT2ACYP2D6POLB
SCHEMBL323955 0.73 SIGMAR1 (0.56) TSHRMEN1ALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) 2023-11-02 US disclosed
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 US disclosed
US-11661580-B2 Method of inhibiting tau phosphorylation CASSAVA SCIENCES, INC. (US) 2023-05-30 US disclosed
EP-4137496-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) 2023-02-22 EP disclosed
US-11385221-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS, INC. (US) 2022-07-12 US disclosed
US-20210389298-A1 Alzheimer's Disease Assay in a Living Patient PAIN THERAPEUTICS, INC. (US) 2021-12-16 US disclosed
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION PAIN THERAPEUTICS, INC. 2021-04-01 US disclosed
US-10760052-B2 Method of inhibiting tau phosphorylation Cassava Science, Inc. (US) 2020-09-01 US disclosed
US-20190271686-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT PAIN THERAPEUTICS, INC. 2019-09-05 US disclosed
US-10017736-B2 Method of inhibiting tau phosphorylation PAIN THERAPEUTICS, INC. (US) 2018-07-10 US disclosed
US-9500640-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS, INC. (US) 2016-11-22 US disclosed
US-9433604-B2 Method for inhibiting growth of cancer cells PAIN THERAPEUTICS INC. (US) 2016-09-06 US disclosed
US-20160251374-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC BURNS BARBIER LINDSAY (US) 2016-09-01 US disclosed
US-9354223-B2 Alzheimer's disease assay in a living patient PAIN THERAPEUTICS INC. (US) 2016-05-31 US disclosed
US-9340558-B2 Filamin a binding anti-inflammatory and analgesic PAIN THERAPEUTICS INC. (US) 2016-05-17 US disclosed
US-20150148318-A1 METHOD FOR INHIBITING GROWTH OF CANCER CELLS PAIN THERAPEUTICS, INC. 2015-05-28 US disclosed
US-20140017698-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT WANG HOAU-YAN (US) 2014-01-16 US disclosed
US-20140018341-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION CASSAVA SCIENCES, INC. 2014-01-16 US disclosed
US-20140017699-A1 ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT CASSAVA SCIENCES, INC. 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348493-A1 COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF GRIN1, GRIN3A, GRIN2C TSHR 2376/4885MEN1 2143/4885ALDH1A1 3847/4885
US-20160251374-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, OPRK1 TSHR 4455/4885MEN1 3737/4885ALDH1A1 2575/4885
US-10760052-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT TSHR 3111/4885MEN1 2287/4885ALDH1A1 4388/4885
US-20140018341-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT TSHR 3111/4885MEN1 2287/4885ALDH1A1 4388/4885
US-20210095248-A1 METHOD OF INHIBITING TAU PHOSPHORYLATION FLNA, FLNB, MAPT TSHR 3111/4885MEN1 2287/4885ALDH1A1 4388/4885
US-11661580-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT TSHR 3111/4885MEN1 2287/4885ALDH1A1 4388/4885
US-10017736-B2 Method of inhibiting tau phosphorylation FLNA, FLNB, MAPT TSHR 3111/4885MEN1 2287/4885ALDH1A1 4388/4885
US-20150148318-A1 METHOD FOR INHIBITING GROWTH OF CANCER CELLS FLNA, FLNB, FSCN1 TSHR 2433/4885MEN1 1816/4885ALDH1A1 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.